LIVE

VRTX

Vertex Pharmaceuticals Incorporated

VRTX

NASDAQ·Healthcare·Biotechnology·Mkt cap $126.4B

$528.04

▲ +6.03%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$362.50 - $529.08

P/E

31.32

Fwd P/E

26.53

Beta

0.31

Div Yield

0.00%

Avg Vol

1.4M

Shares Out

253.8M

Mkt Cap

$126.4B

Price action

Price chart

Up 9.0% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Market leadership in cystic fibrosis treatments
  • Advanced genetic research capabilities
  • Strong intellectual property portfolio
  • Diverse therapeutic pipeline
▼

Bear Case

1 risk

  • Low volatility (beta 0.3).

Growth

Stable outlook

Expanding rare disease treatment market

Value

Fairly valued vs Biotech & Therapeutics peers

Momentum

Strong

+13.5% over 3m

Quality

Excellent

Exceptional business - top-tier fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 3, 2026

“
Q2 26 RECAP

MAY 4, 2026

Reported EPS of $4.47 vs $4.24 consensus (+5.4% surprise). Revenue of $3.0B vs $3.0B expected (-0.2%).

EPS beat +5.4%
Revenue miss

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+5.4%

Next: Aug 3, 2026

Revenue trend · last 8Q

—

—

+16%

+3%

+12%

+11%

+11%

+8%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$2.6B

$2.8B

$2.9B

$2.8B

$3.0B

$3.1B

$3.2B

$3.0B

Margins · last 8Q

Gross

86.8%

Operating

38.1%

Profit

34.5%

View full earnings history →

Wall Street consensus

14 analysts · 79% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

11

79%

Hold

3

21%

Sell

0%

Median Price Target

$557.50

▲ +5.6% vs $528.04

Low $436.00
Median $557.50
High $616.00

Latest: Truist · $542.00 · May 27, 2026

6 analysts covering

View full analyst page →

vs Industry

How VRTX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.